Endo Inc.

LSE:0Y5F Stock Report

Market Cap: US$151.6k

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Endo International Past Earnings Performance

Past criteria checks 0/6

Endo International's earnings have been declining at an average annual rate of -41.7%, while the Pharmaceuticals industry saw earnings declining at 0.9% annually. Revenues have been declining at an average rate of 6.8% per year.

Key information

-41.7%

Earnings growth rate

-40.7%

EPS growth rate

Pharmaceuticals Industry Growth14.1%
Revenue growth rate-6.8%
Return on equityn/a
Net Margin-121.7%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Endo International makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

LSE:0Y5F Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 232,012-2,448568115
30 Sep 232,070-252598118
30 Jun 232,160-942652118
31 Mar 232,182-2,847697119
31 Dec 222,319-2,910758121
30 Sep 222,552-3,221832129
30 Jun 222,783-2,552881123
31 Mar 222,928-681870122
31 Dec 212,993-569841122
30 Sep 212,964129767147
30 Jun 212,827109687150
31 Mar 212,801137688151
31 Dec 202,903247671120
30 Sep 202,908-102661125
30 Jun 203,002-75667133
31 Mar 203,014-190648129
31 Dec 192,914-361632131
30 Sep 192,936-418639122
30 Jun 192,952-522635125
31 Mar 192,967-477630181
31 Dec 182,947-962646186
30 Sep 182,929-968640209
30 Jun 182,971-921612209
31 Mar 183,132-1,565620168
31 Dec 173,469-1,233615172
30 Sep 173,942-4,294666170
30 Jun 174,039-4,386717175
31 Mar 174,084-3,300754185
31 Dec 164,010-3,224771183
30 Sep 163,842553802181
30 Jun 163,704-59760158
31 Mar 163,518-539721126
31 Dec 153,269-300704102
30 Sep 152,858-72559289
30 Jun 152,76612864988
31 Mar 152,624260616100
31 Dec 142,38158568113
30 Sep 142,303-643609116
30 Jun 142,310-637599132
31 Mar 142,429-650722135
31 Dec 132,12518957497
30 Sep 132,621-628829145
30 Jun 132,711-629848157

Quality Earnings: 0Y5F is currently unprofitable.

Growing Profit Margin: 0Y5F is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 0Y5F is unprofitable, and losses have increased over the past 5 years at a rate of 41.7% per year.

Accelerating Growth: Unable to compare 0Y5F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0Y5F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.6%).

Return on Equity

High ROE: 0Y5F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/05/03 16:11
End of Day Share Price 2024/05/03 00:00
Earnings2023/12/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Endo Inc. is covered by 44 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Richard SilverBarclays
Gary NachmanBMO Capital Markets Equity Research
Sumant Satchidanand KulkarniBofA Global Research